Page 34 - Journal of Laparoscopic Surgery - WALS Journal

Hana Alhomoud
10,060 and 10,067, respectively were analyzed. The group. This concludes that a single preoperative dose
CRASH-2 RCT established the safety and efficacy of (10 mg/kg) of TXA given intravenously immediately
TXA administration for trauma patients. It showed a before surgery reduced blood loss during laparoscopic
significant reduction in mortality without any significant sleeve gastrectomy. No thromboembolic incidents,
12
increase in thromboembolic events. Tranexamic acid is adverse reactions, or complications were encountered
thus both safe and effective in reducing the risk of death with the administration of TXA in this study.
due to blood loss in trauma cases. 13
Though the safety and the efficacy of the drug have SUMMARY
been established, there is no consensus about the dosage The aim of this study was to see if TXA given as a short-
and the best time for administration of this drug. The term dose reduced blood loss in laparoscopic sleeve
prescribed dosage is 1–1.5 gm or 15–25 mg/kg two to gastrectomy.
four times daily. The dosage of TXA advocated ranges Tranexamic acid reduces capillary oozing, thus
14
from 1 gm to 100 mg/kg transfused over 15 minutes increasing the operative field visibility. It does not
with a second infusion of 10 mg/kg/hour transfused alter the coagulation profile and no lasting systemic or
until wound closure is achieved. 15 hemodynamic effects were seen in our study.
The dose administered in the CRASH RCT was Tranexamic acid may well be an efficient and cheap
2 gm with 1 gm as bolus and 1 gm as continuous infusion method to control bleeding during laparoscopic sleeve
over the next 8 hours. 12,13 In general surgical conditions gastrectomy.
and in trauma where life-threatening hemorrhages
are anticipated, a continuous infusion is advocated. REFERENCES
However, since laparoscopic sleeve gastrectomy is of
much shorter time duration, we have employed a single 1. Sinder-Pedersen S, Ramstrom G, Bernvil S, Blomback M.
Haemostatic effect of tranexamic acid mouthwash in anti-
bolus administration, preoperatively, in order to prevent coagulant-treated patients undergoing oral surgery. N Engl
intraoperative blood loss. J Med 1989 Mar 30;320(13):840-843.
A total of 148 patients undergoing cardiac surgery 2. Borea G, Montebugnoli L, Capuzzi P, Magelli C. Tranexamic
with extracorporeal circulation were divided into six acid as a mouthwash in anticoagulant-treated patients under-
groups. One group did not receive TXA. The other five going oral surgery: An alternative method to discontinuing
anticoagulant therapy. Oral Surg Oral Med Oral Pathol 1993
received loading doses before incision ranging from 2.5 Jan;75(1):29-31.
to 40 mg/kg, and one-tenth, the loading dose was infused 3. Ramstrom G, Sindert-Pederson S, Hall G, Blomback M,
hourly for 12 hours. The quantity of blood collected by Alander U. Prevention of postsurgical bleeding in oral
test tubes over 12 hours represented blood loss. This surgery using tranexamic acid without dose modification
prospective, randomized, double blind study concluded of oral anticoagulants. J Oral Maxillofac Surg 1993 Nov;
51(11):1211-1216.
that the group that received prophylactic administration 4. Souto JC, Oliver A, Zuazu-Jausoro I, Vives A, Fontcuberta J.
of 10 mg/kg of TXA, followed by continuous infusion of Oral surgery in anticoagulated patients without reducing the
1 mg/kg/hour, had the least hemorrhage. Larger doses dose of oral anticoagulant: a prospective randomized study.
did not provide additional hemostatic benefit. 16 J Oral Maxillofac Surg 1996 Jan;54(1):27-32.
17
Since TXA has a plasma half-life of 1.9 hours, and our 5. Gasper R, Brenner B, Ardekian L, Peled M, Laufer D. Use of
anticipated duration of surgery averaged 2 hours, a bolus tranexamic acid mouthwash to prevent post-operative bleed-
injection of 10 mg/kg weight was chosen as the dosage ing in oral surgery patients on oral anticoagulant medication.
Quintessence Int 1997 Jun;28(6):375-378.
to maintain a therapeutically effective concentration 6. Sindert-Pedersen S, Sternbjerg S. Effect of local antifibrinolytic
between 5 mg/dl. Though 30% of the intravenous dose treatment with tranexamic acid in haemophiliac undergoing
of 10 mg/kg of TXA was detected in the urine during oral surgery. J Oral Maxillofac Surg 1986 Sep;44(9):703-707.
the first hour after administration and the total excretion 7. Kovesi T, Royston D. Pharmacological approaches to reducing
allogenic blood exposure. Vox Sang 2003 Jan;84(1):2-10.
rose to 45% after 3 hours, approximately 55% remains 8. Dunn CJ, Goa KL. Tranexamic acid: a review of its use
18
in circulation up to 24 hours. Therefore, laparoscopic in surgery and other indications. Drugs 1999 Jun;57(6):
sleeve gastrectomy surgery does not require a continuous 1005-1032.
infusion since postoperative hemorrhage is of lesser 9. Sankar D, Krishnan R, Veerabahu M, Vikraman B. Evaluation
concern than management of immediate hemorrhage in of the efficacy of tranexamic acid on blood loss in orthog-
order to clear the field during surgery. nathic surgery: a prospective, randomized clinical study. Int
J Oral Maxillofac Surg 2012 Jun;41(6):713-717.
Our results have shown that none of the TXA patients 10. Athanasiadis T, Beule AG, Wormad PJ. Effects of topical anti-
needed a transfusion and the average fall in hemoglobin fibrinolytics in endoscopic sinus surgery: a pilot randomized
and the volume of blood lost is much less in the TXA controlled trial. Am J Rhinol 2007 Nov-Dec;21(6):737-742.

32